Subtype
Adult Central Nervous System Neoplasm
CI-CAN-00000416Explore in graph →
Non-malignant32 active trials1 evidence items
- NCIt
- C5131
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000416Explore in graph →
Clinical trials
204 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03277638 | Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) | completed | Phase 1 / Phase 2 | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT07243470 | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors(TARLATEM) | recruiting | Phase 1 / Phase 2 | 70 | Centre Leon BerardOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | active not recruiting | Phase 1 | 12 | James Markert, MDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03267836 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | terminated | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | terminated | Phase 1 | 16 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00049127 | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor | completed | Phase 1 / Phase 2 | 64 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma(GLYRad) | completed | Phase 1 / Phase 2 | 18 | Centre Jean PerrinOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)(PARADIGMA) | withdrawn | Phase 1 | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01644955 | Carboplatin in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 10 | James ElderOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials